Teleflex Inc. is making another big investment in a novel product that it believes can boost the revenue growth of its broad product portfolio with the $1.1bn acquisition of privately held NeoTract Inc., manufacturer of the UroLift system for minimally invasive treatment of benign prostate hyperplasia, the companies announced Sept. 5.
Teleflex has agreed to acquire NeoTract for $725m up front, and additional commercial milestone-linked payments of up to $375m over the next three years
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?